CompletedNot Applicable

Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation

Germany340 participantsStarted 2018-10-01

Plain-language summary

Single-arm, prospective observational study

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * all patients after lung transplantation with detection of donor-specific antibodies Exclusion Criteria: * none

Donor-specific Antibodies Clearance

Timeframe: 6, 12, 18, 24 months

NCT IDNCT03798860

SponsorHannover Medical School

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31